TwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued Royalties and Interest

SEATTLE--(BUSINESS WIRE)--TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. District Court for the District of Delaware entered final judgment on Aug. 21, 2026, in favor of TwinStrand and the University of Washington (UW) in their patent infringement suit against Guardant Health, Inc. (Nasdaq: GH). The final judgment preserves a November 2023 jury verdict finding that Guardant Health willfully infringed two core patents underlying T